QURE
HealthcareuniQure N.V. · Biotechnology · $2B
What is uniQure N.V.?
uniQure N.V. is a clinical-stage gene therapy company focused on developing one-time treatments for patients with serious genetic diseases. Headquartered in Amsterdam, the Netherlands, the company targets conditions with limited or no existing therapeutic options.
uniQure designs gene therapies intended to address the root genetic causes of debilitating diseases rather than managing symptoms. The company generates no meaningful product revenue at this stage — its pipeline advances through clinical trials, funded primarily by capital raises and partnerships. Its lead program targets hemophilia B, while additional candidates address Huntington's disease, Parkinson's disease, temporal lobe epilepsy, Alzheimer's disease, and ALS.
uniQure was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- Etranacogene dezaparvovec (AMT-061) — Phase III gene therapy for hemophilia B
- AMT-130 — Phase I/II gene therapy for Huntington's disease
- AMT-210 — product candidate for Parkinson's disease
- AMT-260 — candidate targeting temporal lobe epilepsy
- AMT-240 and AMT-161 — preclinical programs for Alzheimer's disease and ALS
Is QURE a Good Stock to Buy?
UQS Score rates QURE as Poor overall, reflecting the significant challenges common to early-stage gene therapy companies.
The Growth and Risk pillars both land at Neutral, suggesting the pipeline carries some forward potential and that the risk profile is not at the extreme end relative to peers. The company's focus on rare, high-unmet-need diseases does provide a degree of scientific differentiation.
Both the Quality and Moat pillars are rated Weak, consistent with a pre-revenue biotech that lacks durable competitive advantages and generates operating losses. The Valuation pillar is rated Elevated, meaning the current market price appears to price in considerable optimism relative to the company's fundamentals.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does QURE pay dividends?
No — uniQure N.V. does not currently pay a dividend.
uniQure does not pay a dividend. As a clinical-stage company investing heavily in research and development, capital is directed toward advancing its gene therapy pipeline rather than returning cash to shareholders. This is typical for pre-revenue biotechs, where reinvestment into clinical programs is the primary use of available funds.
When does QURE report earnings?
uniQure reports financial results on a quarterly cadence, consistent with US-listed equities.
As a clinical-stage company, quarterly results are driven largely by operating expenses, research costs, and cash runway rather than product revenue. Progress on clinical milestones tends to be the more meaningful signal for investors tracking the business.
For the most recent quarter's results and pipeline updates, visit uniQure's investor relations page directly.
QURE Price History
-49.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in uniQure N.V.?
Based on uniQure N.V.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
QURE Long-term Outlook
The Growth pillar at Neutral reflects a pipeline that holds potential but remains dependent on clinical trial outcomes and regulatory decisions. The Risk pillar also at Neutral suggests the company is not uniquely exposed compared to sector peers, though binary trial events remain a defining feature of the investment profile. With Valuation rated Elevated, the path to justifying the current market price runs through clinical execution rather than near-term financial performance.
Growth drivers
- Advancement of AMT-061 through late-stage hemophilia B trials toward potential approval
- Progression of AMT-130 in Huntington's disease, a high-unmet-need indication with few alternatives
- Expansion of the preclinical pipeline into large neurological disease markets
Key risks
- Clinical trial failure or regulatory setbacks could significantly impair the company's value
- Elevated valuation leaves limited margin of safety if pipeline milestones are delayed
- Ongoing cash consumption without product revenue creates dependence on external financing
QURE vs Peers
uniQure operates in a competitive clinical-stage biotech landscape alongside other companies pursuing novel therapeutic approaches.
ORIC focuses on oncology resistance mechanisms, targeting cancer pathways rather than genetic disease correction.
Aktis Oncology concentrates on targeted radiotherapeutics for cancer, a distinct modality from uniQure's gene therapy approach.
Geron pursues telomerase inhibition in hematologic malignancies, differentiating itself from uniQure's focus on inherited genetic diseases.
Frequently Asked Questions
What does uniQure do?
uniQure is a clinical-stage gene therapy company developing one-time treatments for patients with serious genetic diseases. Its pipeline spans hemophilia B, Huntington's disease, Parkinson's disease, temporal lobe epilepsy, Alzheimer's disease, and ALS. The company aims to address the underlying genetic causes of these conditions rather than managing symptoms long-term.
Does QURE pay dividends?
No, uniQure does not pay a dividend. The company is in a clinical development phase and directs its capital toward advancing its gene therapy pipeline. Investors in QURE are typically seeking potential appreciation from pipeline success rather than income from dividends.
When does QURE report earnings?
uniQure reports on a quarterly cadence, as is standard for US-listed companies. Because it is pre-revenue, clinical trial updates and cash runway disclosures are often as important as the financial figures themselves. Check uniQure's investor relations page for the latest reporting schedule.
Is QURE a good stock to buy?
UQS Score rates QURE as Poor overall, driven by Weak Quality and Moat pillars alongside an Elevated Valuation. That profile reflects the realities of a pre-revenue gene therapy company. Whether it suits an individual portfolio depends on risk tolerance and conviction in the clinical pipeline. The full pillar breakdown is available to Pro members.
Is QURE overvalued?
The UQS Valuation pillar for QURE is rated Elevated, suggesting the current market price reflects considerable optimism relative to the company's present fundamentals. For a clinical-stage biotech, valuation is heavily tied to pipeline probability of success rather than current earnings or cash flow.
How does QURE compare to its competitors?
uniQure competes in the broader clinical-stage biotech space alongside companies like ORIC Pharmaceuticals, Aktis Oncology, and Geron Corporation. Each pursues different therapeutic modalities — uniQure's gene therapy approach to inherited diseases distinguishes it from oncology-focused peers. UQS Score comparative data is available for Pro members.
What is QURE's market cap bracket?
QURE is classified as a small-cap stock. This is typical for clinical-stage gene therapy companies that have not yet reached commercial revenue. Small-cap biotechs can carry higher volatility, as their valuations are sensitive to clinical and regulatory news.
Who founded uniQure?
uniQure traces its origins to 1998. The company's founding history and leadership background are publicly available through its investor relations materials and corporate website, which provide detailed context on its scientific and organizational roots.
Is QURE a long-term quality investment?
As a long-term quality indicator, UQS Score rates QURE as Poor, with Weak scores on both Quality and Moat. Long-term quality typically requires durable competitive advantages and financial stability — characteristics that clinical-stage companies often develop only after achieving commercial success. The pipeline's progress will be the key determinant of future quality ratings.
What is the main competitive advantage of uniQure?
uniQure's scientific focus on gene therapy for rare and underserved genetic diseases provides a degree of differentiation. Its lead programs target conditions with high unmet medical need and limited existing treatments. However, the UQS Moat pillar is rated Weak, reflecting that durable competitive advantages have not yet been established at this stage of development.
What sector does QURE belong to?
QURE operates in the Healthcare sector, specifically within the clinical-stage biotechnology and gene therapy space. Investors can explore other [Healthcare sector stocks](/sector/healthcare) rated by UQS Score to compare quality profiles across the industry.
Unlock Full QURE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare QURE against sector peers side by side
- ✓See the complete risk and valuation breakdown
- ✓Get alerts when QURE's UQS Score changes
Pro Analysis
QURE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 27.5 | 0.8 | 24.0 | 54.9 | 68.9 | 0.0 | +5.0 |
| May 8, 2026 | 22.5 | 0.0 | 24.0 | 54.9 | 36.9 | 0.0 | -3.5 |
| May 7, 2026 | 26.0 | 0.8 | 24.0 | 54.9 | 58.8 | 0.0 | +0.2 |
| Apr 2, 2026 | 25.8 | 0.0 | 24.0 | 54.9 | 58.8 | 0.0 | — |
QURE — Pillar Breakdown
Quality
— 0.8/100 (25%)uniQure N.V. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 54.9/100 (20%)uniQure N.V. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 68.9/100 (15%)uniQure N.V. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)uniQure N.V. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 24/100 (25%)uniQure N.V. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for QURE.
Score Composition
Financial Data
More Stock Analysis
How is the QURE UQS Score Calculated?
The UQS (Unified Quality Score) for uniQure N.V. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses uniQure N.V.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether uniQure N.V. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.